Mid-stage trial data from Beckley Psytech’s intranasal psychedelic compound BPL-003 demonstrated significant symptom reduction in treatment-resistant depression, outperforming a low-dose comparator. The positive Phase 2b results have catalyzed merger plans between Beckley and Atai Life Sciences, which had previously acquired a substantial stake in Beckley. The emerging evidence supports the growing momentum and regulatory interest in psychedelic therapies for mental health, with attention to safety and efficacy profiles essential to future development and commercialization.